Vasopressin und Terlipressin beim vasodilatatorischen Schock

Eine wichtige Komponente der Therapie des vasodilatatorischen Schockgeschehens im Rahmen der Intensivmedizin ist der Einsatz von Katecholaminen. Bei prolongierter Anwendung kommt es jedoch zur Wirkungsverminderung durch Abnahme der Rezeptorzahl („Down-Regulation“) und Verminderung der Rezeptorsensibilität (Desensibilisierung). Die Möglichkeit, diesem Effekt durch zusätzliche Gabe von Vasopressin und dessen Analogon Terlipressin entgegenzuwirken, haben Serpa Neto und Kollegen im Rahmen einer Metaanalyse untersucht.

• Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122-1125
• Russell J, Walley K, Singer J et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. N Engl J Med 2008; 358: 877-887
• Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327
• Torgersen C, Dunser MW, Schmittinger CA et al. Current approach to the haemodynamic management of septic shock patients in European intensive care units: a cross-sectional, self-reported questionnaire-based survey. Eur J Anaesthesiol 2011; 28: 284-290
• Serpa Neto A, Nassar Junior AP, Cardoso SO et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care 2012; 16
• Luckner G, Dunser MW, Jochberger S et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33: 2659-2666
• Russell JA, Walley KR, Gordon AC et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37: 811-818
• Torgersen C, Luckner G, Schroder DC et al. Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality. Intensive Care Med 2011; 37: 1432-1437
• Torgersen C, Dunser MW, Wenzel V et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010; 36: 57-65
• Rehberg S, Yamamoto Y, Sousse LE et al. Selective V1a agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol [Epub ahead of print] 2012;
• Argenziano M, Choudhri AF, Oz MC et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96: 286-290
• Rehberg S, Ertmer C, Vincent JL et al. Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med 2011; 39: 119-125
• Rehberg S, Ertmer C, Kohler G et al. Role of arginine vasopressin and terlipressin as first-line vasopressor agents in fulminant ovine septic shock. Intensive Care Med 2009; 35: 1286-1296
• Morelli A, Ertmer C, Rehberg S et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009; 13
• Nakada TA, Russell JA, Wellman H et al. Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 2011; 139: 1042-1049